Graphic Health Warnings on Cigarette Packaging Delayed Until 2023

Nov.16.2022
Graphic Health Warnings on Cigarette Packaging Delayed Until 2023
Graphic health warnings for cigarettes delayed until November 2023, per a Texas court order.

It won't be until early November 2023 that cigarette packaging and advertisements will feature graphic health warnings.


The Eastern District Court of Texas in the United States has issued an order to further delay the effective date of the Food and Drug Administration's (FDA) graphic cigarette health warning regulation from October 6, 2023, to November 6, 2023, for an additional 31 days.


According to the National Association of Tobacco Outlets (NATO), a court order issued on November 7 has extended the deadline for manufacturers and retailers to submit their preferred rotation plans for cigarette health warning labels to the FDA by 31 days.


Every tobacco manufacturer and retailer who makes their own cigarette advertisements is required to submit a plan to the FDA that outlines a schedule for rotating the use of 11 graphic cigarette health warnings in their ads. The association stated that the preferred submission deadline for the cigarette health warning rotation plan is now January 6, 2023.


According to NATO, the court is expected to make a ruling on the motion for summary judgment in the case within 31 days.


In March 2020, the FDA released a final rule about warnings that includes text and image combinations that describe some of the health risks associated with smoking. However, implementation has been repeatedly delayed after several tobacco companies requested a specific date be set.


The Eastern District Court of Texas has postponed the deadline for the final time on August 20, setting the new deadline for October 6, 2023.


These warnings must appear on the top 50% of the front and back of cigarette packaging, as well as on at least 20% of the top of cigarette advertisements. Additionally, as previously reported by Convenience Store News, these warnings must be randomly and evenly displayed and distributed on cigarette packaging, and rotated quarterly in cigarette advertisements.


There are 11 essential warnings that need to be addressed. They include:


Warning: Tobacco smoke can harm your children. Warning: Tobacco smoke can cause deadly lung diseases in non-smokers. Warning: Smoking can lead to head and neck cancer. Warning: Smoking can cause bladder cancer, leading to blood in urine. Warning: Smoking during pregnancy can hinder fetal growth. Warning: Smoking can block arteries, leading to heart disease and stroke. Warning: Smoking can cause chronic obstructive pulmonary disease, a potentially fatal lung disease. Warning: Smoking can decrease blood flow and cause erectile dysfunction. Warning: Smoking can decrease blood flow to the limbs, possibly requiring amputation. Warning: Smoking can cause type 2 diabetes, raising blood sugar. Warning: Smoking can cause cataracts, leading to blindness.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Company Limited announced its audited results for the year ended December 31, 2025. Revenue was HK$14.58 billion, profit before taxation was HK$1.28 billion, and profit attributable to owners of the Company was HK$0.98 billion, with basic and diluted EPS of HK$1.42. The Board proposed a final dividend of HK$0.33 per share; together with an interim dividend of HK$0.19 per share, the full-year dividend totaled HK$0.52 per share.
Mar.06 by 2FIRSTS.ai
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
China Tobacco Jiangsu IC appears to have developed a nicotine oral film product under the "Nanjing" brand, according to images circulating on Chinese social media. If confirmed, this could potentially mark China Tobacco's first oral nicotine product targeting the domestic market. The product's authenticity has not been officially verified, and no nicotine pouch products have been approved for sale in China.
Special Report
Feb.09
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
More than 2,300 units of vape liquid worth over RM75,000 were seized during an integrated operation at premises in Likas near Kota Kinabalu. During Ops Taring Landai E-Cigarette Mega on Feb 10 night, the Marine Police, Sabah Health Department officials and district police detected a shop displaying 92 types of vape pods and, after further searches, found 2,353 units of vape liquid stored on the premises.
Feb.11 by 2FIRSTS.ai
South Korea’s Revised Tobacco Business Act to Take Effect, With Penalties for Unauthorized Sales
South Korea’s Revised Tobacco Business Act to Take Effect, With Penalties for Unauthorized Sales
With the revised Tobacco Business Act set to take effect on April 24, synthetic nicotine e-cigarettes will be included within the legal definition of tobacco in South Korea. According to information released by Ongjin County, businesses wishing to sell these products must obtain tobacco retailer designation from the relevant authority.
Mar.25 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03